ATE422857T1 - Induktion von immunologischer toleranz - Google Patents

Induktion von immunologischer toleranz

Info

Publication number
ATE422857T1
ATE422857T1 AT05012607T AT05012607T ATE422857T1 AT E422857 T1 ATE422857 T1 AT E422857T1 AT 05012607 T AT05012607 T AT 05012607T AT 05012607 T AT05012607 T AT 05012607T AT E422857 T1 ATE422857 T1 AT E422857T1
Authority
AT
Austria
Prior art keywords
tissue
implanted
cell
induction
organs
Prior art date
Application number
AT05012607T
Other languages
English (en)
Inventor
Paul P Latta
Original Assignee
Paul P Latta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul P Latta filed Critical Paul P Latta
Application granted granted Critical
Publication of ATE422857T1 publication Critical patent/ATE422857T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
AT05012607T 1995-10-26 1996-10-25 Induktion von immunologischer toleranz ATE422857T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US587795P 1995-10-26 1995-10-26

Publications (1)

Publication Number Publication Date
ATE422857T1 true ATE422857T1 (de) 2009-03-15

Family

ID=21718169

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96937029T ATE297702T1 (de) 1995-10-26 1996-10-25 Induktion von immunologischer toleranz
AT05012607T ATE422857T1 (de) 1995-10-26 1996-10-25 Induktion von immunologischer toleranz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96937029T ATE297702T1 (de) 1995-10-26 1996-10-25 Induktion von immunologischer toleranz

Country Status (6)

Country Link
US (5) US20020192190A1 (de)
EP (2) EP0955948B1 (de)
AT (2) ATE297702T1 (de)
AU (1) AU7479596A (de)
DE (2) DE69637842D1 (de)
WO (1) WO1997015243A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637842D1 (de) * 1995-10-26 2009-04-02 Paul P Latta Induktion von immunologischer Toleranz
AU3745900A (en) * 1999-03-15 2000-10-04 Modex Therapeutiques, S.A. Methods and compositions for tolerizing hosts for long term survival of tissue transplants
US20020012667A1 (en) * 2000-05-16 2002-01-31 Mcmichael John Method for preventing allograft rejection
WO2008027420A2 (en) * 2006-08-29 2008-03-06 The University Of Akron Implantable devices for producing insulin
US20100196439A1 (en) * 2006-12-22 2010-08-05 Medtronic, Inc. Angiogenesis Mechanism and Method, and Implantable Device
CN101896188B (zh) * 2007-10-15 2013-01-02 弗雷森纽斯医疗护理德国有限责任公司 微泡(mv)用于制备对内皮细胞移植具有佐剂活性、特别是对通过胰岛移植进行的糖尿病治疗具有佐剂活性的药物的用途，和相关方法
WO2010032242A1 (en) * 2008-09-17 2010-03-25 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
EP3290061B1 (de) 2009-08-28 2020-06-10 Sernova Corporation Verfahren und vorrichtungen für zelltransplantation
WO2011154941A2 (en) 2010-06-07 2011-12-15 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
EP3522850B1 (de) * 2016-10-05 2023-12-27 Arizona Board of Regents on behalf of the University of Arizona Verfahren und systeme zur verbesserung der immunsystemreaktionen
US10973956B2 (en) * 2017-01-05 2021-04-13 The Regents Of The University Of Michigan Microporous hydrogel scaffolds for cell transplantation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4378016A (en) * 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
CA1196862A (en) * 1983-06-01 1985-11-19 Anthony M.F. Sun Microencapsulation of living tissue and cells
US4806355A (en) * 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4689293A (en) * 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
AU3542684A (en) 1983-11-15 1985-05-23 Johnson & Johnson Corporation Glycemia regulating implant
NO166836C (no) * 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
US4997443A (en) * 1985-08-26 1991-03-05 Hana Biologics, Inc. Transplantable artificial tissue and process
US4902295A (en) * 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
CA2081782C (en) * 1990-05-16 2004-08-24 James H. Kelly Permanent human hepatocyte cell line and its use in a liver assist device (lad)
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
CA2034641A1 (en) 1990-11-27 1992-05-28 Gudmund Skjak-Braek Homologous guluronic acid alginate coating composition for in-vivo application and implatation and method of using same
EP0585368B1 (de) 1991-04-25 1997-08-06 Brown University Research Foundation Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
GB9120776D0 (en) * 1991-10-01 1991-11-13 Shell Int Research Process for upgrading a hydrocarbonaceous feedstock and apparatus for use therein
US5425764A (en) * 1992-07-30 1995-06-20 The University Of Toledo Bioartificial pancreas
US5262055A (en) * 1992-10-19 1993-11-16 The University Of Utah Implantable and refillable biohybrid artificial pancreas
AU7404494A (en) * 1993-07-21 1995-02-20 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5629194A (en) * 1994-10-21 1997-05-13 Diacrin, Inc. Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
DE69637842D1 (de) * 1995-10-26 2009-04-02 Paul P Latta Induktion von immunologischer Toleranz

Also Published As

Publication number Publication date
US7361333B2 (en) 2008-04-22
DE69637842D1 (de) 2009-04-02
US20100260816A1 (en) 2010-10-14
EP1586284B1 (de) 2009-02-18
US20020192190A1 (en) 2002-12-19
WO1997015243A1 (en) 1997-05-01
EP1586284A1 (de) 2005-10-19
US7361334B2 (en) 2008-04-22
EP0955948B1 (de) 2005-06-15
EP0955948A4 (de) 1999-11-17
US20040191227A1 (en) 2004-09-30
DE69634859D1 (de) 2005-07-21
AU7479596A (en) 1997-05-15
US20040047848A1 (en) 2004-03-11
ATE297702T1 (de) 2005-07-15
EP0955948A1 (de) 1999-11-17
US20080317770A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
ATE308926T1 (de) Nicht antigenische und durch peressigsäure vernetzte transplantate mit innerer kollagenschicht
DE69714083D1 (de) Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
ATE142693T1 (de) Herstellung des vaskulären endothelialen zellwachstumsfaktors
DE59610355D1 (de) Medizinisches implantat
FR2701648B1 (fr) Prothèse destinée au traitement d'une lumière ou voie naturelle, notamment prothèse endo-uréthrale.
DE69637842D1 (de) Induktion von immunologischer Toleranz
ATE433998T1 (de) Divalent anti-t-zellen immuntoxinen und deren verwendung
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
PT941329E (pt) Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
ATE261735T1 (de) Verwendung von wirkstoffen zur herstellung von arzeinmitteln zur behandlung der rheumatischen arthritis
ES2002127A6 (es) Procedimiento para extraer los colagenos placentarios
GB9617611D0 (en) Treatment of autoimmune disease
HK1021318A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
Kortholm Transplantation between monozygotic twins
EP0668771A4 (de) Behandlung von autoimmunkrankheiten durch hervorrüfen von toleranz in zellen, geweben und organen.
developing counties like India Prof. Dr. Ashraf Ganatra
PEER et al. Behavior of a first, second and third crop of skin homografts from the same donor
DE3877102T2 (de) Methode fuer die behandlung von viraler gehirnentzuendung.
Piot International treatment access and research, how you can help--interview with Dr. Peter Piot of UNAIDS. Joint United Nations Programme on HIV/AIDS. Interview by John S. James
Levy et al. Gerontology and the Practice of Geriatric Dentistry 1
Rogers Progress towards the eradication of leprosy from the british commonwealth

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties